Insider Trading

BLUE Stock  USD 0.38  0.01  2.56%   
About 61% of Bluebird Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Bluebird bio suggests that many traders are alarmed. The current market sentiment, together with Bluebird Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Bluebird bio stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Bluebird bio Executive. Insider Public Trading

Read at macroaxis.com
Bluebird insider trading alert for general transaction of by Cloonan Michael, Executive, on 20th of June 2024. This event was filed by Bluebird bio with SEC on 2024-06-20. Initial filing of beneficial ownership - SEC Form 3

Bluebird Bio Fundamental Analysis

We analyze Bluebird Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluebird Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluebird Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Bluebird Bio is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Bluebird bio Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bluebird Bio stock to make a market-neutral strategy. Peer analysis of Bluebird Bio could also be used in its relative valuation, which is a method of valuing Bluebird Bio by comparing valuation metrics with similar companies.

Peers

Bluebird Bio Related Equities

HEPAHepion Pharmaceuticals   5.08   
0%
35.0%
SRPTSarepta Therapeutics   0.73   
5.0%
0%
MDGLMadrigal Pharmaceuticals   1.33   
9.0%
0%
KPTIKaryopharm Therapeutics   1.37   
9.0%
0%
CVACCureVac NV   2.14   
15.0%
0%
YMABY MAbs   2.40   
16.0%
0%
VKTXViking Therapeutics   2.72   
19.0%
0%
TVTXTravere Therapeutics   4.12   
29.0%
0%
PTCTPTC Therapeutics   4.65   
32.0%
0%
VIRVir Biotechnology   4.99   
35.0%
0%
KRYSKrystal Biotech   7.33   
51.0%
0%
ZNTLZentalis Pharmaceuticals   10.57   
74.0%
0%
AGIOAgios Pharm   11.99   
84.0%
0%
MRSNMersana Therapeutics   14.18   
100.0%
0%

Complementary Tools for Bluebird Stock analysis

When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance